Mabaga, Madeleine G.
HRN: 13-79-75 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/08/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
06/08/2022
06/09/2022
IV
500 Mg
Q8 X 7 Doses
S/p LTCS II Followed By Bilateral Salphingectomy, Thinly Meconuium Stained AF
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes